scPharmaceuticals (SCPH) News Today $3.36 -0.16 (-4.55%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period FY2024 EPS Forecast for scPharmaceuticals Lowered by AnalystNovember 20 at 1:53 AM | americanbankingnews.comHC Wainwright Has Bearish Estimate for SCPH FY2024 EarningsscPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) - Investment analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of scPharmaceuticals in a note issued to investors on Thursday, November 14th. HC Wainwright analyst D. Tsao now expects that the company wiNovember 18 at 1:49 AM | marketbeat.comEarnings Update: scPharmaceuticals Inc. (NASDAQ:SCPH) Just Reported And Analysts Are Trimming Their ForecastsNovember 16, 2024 | finance.yahoo.comscPharmaceuticals Inc. (NASDAQ:SCPH) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | insidermonkey.comPositive Outlook for scPharmaceuticals: Strategic Growth and Regulatory Milestones Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comscPharmaceuticals price target lowered to $12 from $16 at Craig-HallumNovember 15, 2024 | markets.businessinsider.comPositive Buy Rating for scPharmaceuticals Driven by Strong Furoscix Launch and Strategic Growth InitiativesNovember 14, 2024 | markets.businessinsider.comscPharmaceuticals Inc. (SCPH) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comscPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | globenewswire.comscPharmaceuticals's Earnings OutlookNovember 12, 2024 | benzinga.comscPharmaceuticals (SCPH) Set to Announce Quarterly Earnings on WednesdayNovember 12, 2024 | americanbankingnews.comscPharmaceuticals (SCPH) Set to Announce Earnings on WednesdayscPharmaceuticals (NASDAQ:SCPH) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comscPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024November 6, 2024 | globenewswire.comRice Hall James & Associates LLC Increases Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)Rice Hall James & Associates LLC raised its stake in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 25.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 621,665 shares of the company's stoNovember 2, 2024 | marketbeat.comStrategic Growth and Market Expansion Opportunities Drive Buy Rating for scPharmaceuticalsOctober 25, 2024 | markets.businessinsider.comStrategic Buy Rating for scPharmaceuticals: Furoscix’s Potential in CKD MarketOctober 25, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on scPharmaceuticals (SCPH)October 24, 2024 | markets.businessinsider.comCraig-Hallum Remains a Buy on scPharmaceuticals (SCPH)October 24, 2024 | markets.businessinsider.comscPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024October 15, 2024 | globenewswire.comSafety Data Favor Diuretic Strategy Triggered by Cardiac Monitoring Alerts in HFOctober 11, 2024 | msn.comBank of Montreal Can Makes New $1.54 Million Investment in scPharmaceuticals Inc. (NASDAQ:SCPH)Bank of Montreal Can purchased a new stake in scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 351,806 shares of the company's stockOctober 5, 2024 | marketbeat.comscPharmaceuticals Inc. (NASDAQ:SCPH) Sees Large Drop in Short InterestscPharmaceuticals Inc. (NASDAQ:SCPH - Get Free Report) was the target of a significant decline in short interest in September. As of September 15th, there was short interest totalling 4,250,000 shares, a decline of 15.0% from the August 31st total of 5,000,000 shares. Based on an average daily volume of 264,000 shares, the short-interest ratio is currently 16.1 days.September 28, 2024 | marketbeat.comscPharmaceuticals Inc. (NASDAQ:SCPH) Shares Bought by King Luther Capital Management CorpKing Luther Capital Management Corp grew its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 51.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,205,140 shares of the company'September 21, 2024 | marketbeat.comInvestors in scPharmaceuticals (NASDAQ:SCPH) have unfortunately lost 23% over the last yearSeptember 16, 2024 | finance.yahoo.comRice Hall James & Associates LLC Has $2.16 Million Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)Rice Hall James & Associates LLC increased its stake in scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 76.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 497,227 shares of the company's stock after purchasing an additional 216,122 sharesSeptember 12, 2024 | marketbeat.comscPharmaceuticals Inc. (NASDAQ:SCPH) Shares Bought by AIGH Capital Management LLCAIGH Capital Management LLC lifted its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 3.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,504,365 shares of the company's stSeptember 9, 2024 | marketbeat.comscPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | markets.businessinsider.comAssenagon Asset Management S.A. Buys 52,870 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)Assenagon Asset Management S.A. increased its stake in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 266.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 72,692 shares of the company's stock after buying an additional 52,870 shares duringAugust 25, 2024 | marketbeat.comHC Wainwright Analysts Raise Earnings Estimates for scPharmaceuticals Inc. (NASDAQ:SCPH)scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) - Research analysts at HC Wainwright raised their Q3 2024 EPS estimates for scPharmaceuticals in a note issued to investors on Monday, August 19th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($0.28) per shaAugust 21, 2024 | marketbeat.comAfter losing 35% in the past year, scPharmaceuticals Inc. (NASDAQ:SCPH) institutional owners must be relieved by the recent gainAugust 20, 2024 | finance.yahoo.comBuy Rating Affirmed: scPharmaceuticals’s Revenue Surge and Product Development PromiseAugust 18, 2024 | markets.businessinsider.comscPharmaceuticals Inc. (NASDAQ:SCPH) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | msn.comQ2 2024 EPS Estimates for scPharmaceuticals Inc. (NASDAQ:SCPH) Decreased by Leerink PartnrsscPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) - Research analysts at Leerink Partnrs lowered their Q2 2024 earnings per share (EPS) estimates for shares of scPharmaceuticals in a note issued to investors on Monday, August 12th. Leerink Partnrs analyst R. Ruiz now expects that the company wilAugust 15, 2024 | marketbeat.comSCPH Stock Earnings: scPharmaceuticals Misses EPS, Misses Revenue for Q2 2024August 14, 2024 | investorplace.comscPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | globenewswire.comscPharmaceuticals earnings preview: what to expectAugust 13, 2024 | markets.businessinsider.comSGLT2 Hesitance; Furosemide's Indication Grows; Legal Fight Over Entresto GenericAugust 13, 2024 | msn.comBuy Rating Affirmed for scPharmaceuticals Amidst FDA Approval and Strong Financial PerformanceAugust 13, 2024 | markets.businessinsider.comUnited Community Banks Second Quarter 2024 Earnings: Beats ExpectationsAugust 12, 2024 | uk.finance.yahoo.comScPharma's FUROSCIX Expanded Indication In Heart Failure Gets FDA Approval; Stock Down In Pre-marketAugust 12, 2024 | markets.businessinsider.comCraig-Hallum Gives a Buy Rating to scPharmaceuticals (SCPH)August 12, 2024 | markets.businessinsider.comScPharmaceuticals Announces Proposed Underwritten Public Offering - Quick FactsAugust 12, 2024 | markets.businessinsider.comHeart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand CommercializationAugust 12, 2024 | msn.comscPharmaceuticals Announces Pricing of $50.0 Million Public OfferingAugust 12, 2024 | globenewswire.comscPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive AdvisorsAugust 12, 2024 | globenewswire.comscPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart FailureAugust 12, 2024 | globenewswire.comscPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) AutoinjectorAugust 12, 2024 | globenewswire.comscPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsAugust 12, 2024 | globenewswire.comscPharmaceuticals (SCPH) to Release Earnings on WednesdayscPharmaceuticals (NASDAQ:SCPH) will be releasing earnings after the market closes on Wednesday, August 14, Zacks reports.August 9, 2024 | marketbeat.comHe's helped 11 biotechs go public — without a science backgroundAugust 2, 2024 | bizjournals.com Get scPharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide SCPH Media Mentions By Week SCPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SCPH News Sentiment▼-0.300.45▲Average Medical News Sentiment SCPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SCPH Articles This Week▼122▲SCPH Articles Average Week Get scPharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Chimerix News OptiNose News Fortress Biotech News Mustang Bio News Aquestive Therapeutics News Entrada Therapeutics News Arbutus Biopharma News Dianthus Therapeutics News CorMedix News Tectonic Therapeutic News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SCPH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
